Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme

Showing 1 to 10 of 2144

TitleReference numberPublishedLast updated
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA1064
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatmentTA1063
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitorTA1062
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1060
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphomaTA1059
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessmentHTE25
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)TA1061
Drug-eluting stents for treating coronary artery disease: late-stage assessmentHTE26
Cenobamate for treating focal onset seizures in epilepsyTA753
Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessmentHTE24

Results per page

  1. 10
  2. 25
  3. 50
  4. All